BPC-157: Research Chemistry and Literature

BPC-157 is a synthetic pentadecapeptide. Its fifteen residues run Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, giving a free-peptide formula of C62H98N16O22 and an average mass close to 1419.5 daltons. No cysteine is present, so there is no disulfide bridge to reduce or scramble. Three consecutive prolines occupy positions three through five, and that block together with the acidic pair at Asp10 and Asp11 governs how the chain behaves in solution. The residue tally runs three acidic against one basic, leaving the free peptide with a net negative charge at neutral pH.

The sequence was not designed from scratch. It was read off a larger protein characterised in human gastric juice, described in the early literature as body protection compound, and the fifteen-residue fragment was first reported by Sikiric and colleagues in 1993. Sequence searches against catalogued gastrointestinal peptides return no meaningful homology, so the literature treats BPC-157 as its own entity rather than an analogue of a known signalling peptide. Material supplied for laboratory work is built by solid-phase synthesis and is not extracted from tissue.

Reference data

CAS number: 137525-51-0
Chemical formula: C62H98N16O22
Molar mass: 1419.53 g/mol
Shelf life: 36 months

Origin and identification

The parent material came out of work on human gastric secretions. Investigators looking at gastric juice in the late 1980s and early 1990s isolated a protein fraction that survived acidic conditions, and a fifteen-residue stretch of that fraction was carried forward under the BPC 157 designation. The first formal description dates to 1993. Two orthographies persist in the record, BPC 157 with a space and BPC-157 with a hyphen, and both point at the same sequence.

Development codes complicate a literature search. The same peptide appears as PL-10, PLD-116 and PL 14736 in material originating from Pliva in Croatia, where it moved into formal study through the 1990s and 2000s. A bibliography assembled on the common name alone will miss a substantial part of the record. PubChem indexes the free peptide under CID 9941957. An acetate salt is indexed separately, and that distinction matters when a stated mass on a supplier record is reconciled against a reference value, since the counter-ion contributes mass the free peptide does not carry.

Preclinical research context

The published work is overwhelmingly rodent. Male Wistar rats account for the bulk of the in vivo record, with mice appearing far less often. Gastrointestinal models came first. Protocols using chemically provoked mucosal lesions, alcohol challenge and non-steroidal anti-inflammatory challenge form the earliest body of work, and the endpoints there are histological scoring of mucosal integrity alongside gross lesion area.

Musculoskeletal models followed and now dominate the recent literature. Transected Achilles tendon, transected medial collateral ligament and transected quadriceps preparations in rats have all been reported, generally with tensile testing, functional scoring and histology sampled at fixed intervals out to ninety days. In vitro assays sit alongside the animal work. Tendon explant outgrowth, tendon fibroblast migration and hydrogen-peroxide survival assays have been used to interrogate cellular behaviour apart from the whole organism.

A vascular thread runs through the later reviews. Angiogenesis and nitric oxide signalling are the framing that authors reach for, and vascular recruitment has been proposed as a single account tying together observations that otherwise span unrelated organ systems. The proposal remains contested. No major regulator has approved the compound, and the reviews arguing hardest for a mechanism are candid that controlled human data are sparse. BPC-157 also appears in anti-doping method development, a separate literature with separate aims, and that work is a useful source of analytical detail.

Analytical characterisation

Chromatographic purity is established by reverse-phase HPLC. A C18 stationary phase with a water and acetonitrile gradient modified with trifluoroacetic acid is the conventional system, and UV detection at 210 nanometres reads the amide backbone rather than aromatic absorbance, which this sequence lacks entirely. Purity is reported as main-peak area against total integrated area. Deletion sequences and proline-related isomers, where they occur, tend to elute close to the parent peak, so gradient shallowness carries more weight here than it would for a shorter chain.

Identity is confirmed by mass spectrometry. Electrospray ionisation produces a multiply charged envelope that deconvolutes to a sequence-consistent average mass near 1419.5 daltons. A measured value outside a narrow window points at a truncation, an incomplete deprotection or a salt form other than the one declared. Tandem fragmentation resolves the sequence itself when a purity figure alone will not settle the question. Certificates of Analysis for this catalogue are commissioned from Janoshik Analytical, and each report pairs the chromatogram with the mass spectrum so purity and identity can be read together rather than taken on assertion.

Handling and storage

The lyophilised powder tolerates ambient conditions in transit. Peptides of this length ship without cold chain as a matter of routine, and brief exposure to warm conditions during carriage does not compromise a dry, sealed vial. Check the seal and the desiccant on arrival before anything else.

On receipt, hold the sealed vial at minus 20 degrees Celsius and keep it dark. Amber glass or an opaque secondary container will do. A freezer without a viewing window is better. Let the vial reach room temperature before opening it, otherwise atmospheric moisture condenses onto cold powder, which is the most common route by which a dry peptide picks up water it was never meant to hold.

Reconstituted material is a different proposition. Hold it at 2 to 8 degrees Celsius and treat its useful window as short. Repeated freeze-thaw cycling degrades peptide solutions faster than storage temperature alone accounts for, so divide the solution into single-use aliquots before the first freeze rather than returning a stock vial to the freezer over and over. Mark each aliquot with the date it was prepared and the solvent used.

References

Related compounds

GHK-Cu MOTS-c KPV DSIP Tesamorelin MT-1

This page summarises published laboratory research for reference purposes. Materials described are supplied for in vitro and analytical research use only. Not for human or veterinary consumption.